Search

News Expert Consensus on the Use of Bimekizumab in the Treatment of Plaque Psoriasis and Psoriatic Arthritis

The expert consensus published in February 2024 offers guidance on the use of bimekizumab in the treatment of patients with moderate to severe plaque psoriasis and psoriatic arthritis. It is based on a literature review and an assessment of data from 19 relevant studies. A panel of 9 American dermatologists specializing in psoriasis treatment created and adopted 14 consensus statements and recommendations, 12 of which have a strength of “A”.

Source: Psoriasis 16. 5. 2024

News What is the Impact of Bisoprolol on Plasma Concentrations of Dabigatran

Many patients on anticoagulant therapy with dabigatran also use the beta-blocker bisoprolol. The Slovak prospective observational study was based on the assumption that bisoprolol, as a significant inhibitor of P-glycoprotein, may interact with dabigatran and focused on examining the effect of this beta-blocker on plasma concentrations of dabigatran.

Source: Cardiovascular Continuum 16. 9. 2022

News Dual Inhibition of IL-17A/IL-17F Across the Spectrum of Axial Spondyloarthritis

Many patients with axial spondyloarthritis (axSpA) still have a need to seek additional therapeutic options and new mechanisms of action for medicinal substances. Phase III studies BE MOBILE 1 and 2 therefore evaluated the effect of administering bimekizumab—a monoclonal antibody selectively inhibiting interleukins (IL) 17A and 17F—across the full spectrum of patients with axSpA.

Source: Rheumatic Diseases 1. 12. 2023

News Safety and Efficacy of Long-term Tofacitinib Therapy in Patients with Active Psoriatic Arthritis –⁠ Interim Results of the OPAL Balance Study

Tofacitinib is a potent selective inhibitor of the Janus kinase (JAK) family indicated for the treatment of active psoriatic arthritis in adult patients. The efficacy and safety of tofacitinib in this population have been verified for 6 and 12 months through clinical studies OPAL. A study published in 2020 presents interim results of the extended phase of these studies, evaluating its efficacy and safety in the long term.

Source: Arthritis 30. 5. 2022

News Improvement of Joint and Skin Symptoms and Their Contribution to Improving the Quality of Life in Patients with Psoriatic Arthritis

The cause of reduced quality of life in patients with psoriatic arthritis is the involvement of both skin and joints. Commonly used therapy certainly improves symptoms of both systems to some extent, but to what extent does this improvement correlate with a higher health-related quality of life? This question was addressed by analyzing two randomized studies.

Source: Biological Treatment 21. 8. 2020

News Venetoclax in the Treatment of CLL: Open Doors for the Longest Possible Maintenance of Remission Without Active Therapy

William G. Wierda from MD Anderson Cancer Center in Houston, USA, and Francesco P. Tambaro from Azienda Ospedaliera di Rilievo Nazionale Santobono-Pausilipon in Naples, Italy, evaluate in their report for the journal Blood from April 2020 the practical aspects and benefits of using venetoclax in the first-line treatment of chronic lymphocytic leukemia (CLL), as well as in cases of relapsing/refractory forms of the disease.

Source: Chronic Lymphocytic Leukemia 8. 6. 2020

News An Introductory Word to the Section on Hereditary Angioedema —⁠ MUDr. Roman Hakl, Ph.D.

Hereditary angioedema (HAE) is a genetically conditioned disease, currently classified into HAE with C1 inhibitor deficiency (HAE-C1-INH), referred to as HAE-I and HAE-II, and HAE with normal level and function of C1 inhibitor (HAE nC1-INH), also referred to as HAE-III (1).

Source: Hereditary Angioedema 29. 7. 2020

News Reduction of Risk of Hospitalizations for Heart Failure in Type 2 Diabetics

The EMPA-REG OUTCOME study already in 2015 highlighted one of the benefits of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, which is the reduction of the risk of hospitalization for heart failure in patients with type 2 diabetes mellitus (T2DM) with high cardiovascular (CV) risk. Compared to placebo, empagliflozin reduced this risk by a relative 35%.

Source: Heart Failure 2. 12. 2021

News New scoring system for predicting long-term survival of AML patients over 70 years and suitable for intensive chemotherapy

Based on the analysis of data from 3 large European registries (DATAML, SAL, and PETHEMA), a prognostic score for 5-year survival was created and validated for patients with acute myeloid leukemia (AML) who were given intensive chemotherapy. The ESS70+ score, determined based on parameters known at the time of diagnosis, is easily usable in routine practice for estimating overall survival of older AML patients and facilitates decisions about intensive chemotherapy.

Source: Acute Myeloid Leukemia 10. 5. 2024

News Correlation of Levothyroxine Dose with Autoimmune Antibody Titer in Primary Hypothyroidism

The relationship between the level of antithyroid antibodies and the required dose of levothyroxine in substitution for autoimmune hypothyroidism is a poorly explored question. Therefore, a retrospective study of more than 300 patients was conducted, and we bring you a brief summary.

Source: Thyroid Disorders 14. 9. 2022

News Treatment of Comorbidities of Atopic Dermatitis in One Go and Where to Refer Candidates for Biologic Therapy

Patients suffering from atopic dermatitis (AD) along with allergic comorbidities typically require a fairly complex pharmacotherapy to manage their difficulties. However, their everyday lives can be significantly simplified with biological therapy.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 19. 10. 2020

News Virtual Echocardiography as a Potential Screening Tool for the Diagnosis of Primary Pulmonary Hypertension

Primary pulmonary hypertension disease is associated with a poor prognosis. Early diagnosis and the implementation of specific therapy are necessary to improve patients' prospects. In the near future, virtual echocardiography, which has shown good results in published studies, may become a valuable screening tool.

Source: Pulmonary hypertension (CTEPH, PAH) 10. 3. 2021

News New ESMO Recommendations for Investigating Circulating Tumor DNA

Liquid biopsy has been discussed in oncology for several decades. As we move from conference abstracts to its real-world application in clinical practice, the new recommendations of the European Society for Medical Oncology (ESMO) describe the examination of circulating tumor DNA from peripheral blood.

Source: Genetic Profile and Treatment of NSCLC 8. 9. 2022

Články časopisu Non-Small Cell Lung Cancer with Estrogen Receptors and ALK Positivity

Author of the article: L. Žarnayová, V. Kolek, J. Bouchal, J. Ehrmann Source: Klinická onkologie | 6/2018 11. 12. 2018

News Impact of Comorbidities on the Efficacy of Ceftaroline Fosamil in Complicated Skin and Soft Tissue Infections −⁠ Pooled Analysis of 3 Studies

In 3 randomized Phase III studies, ceftaroline fosamil demonstrated non-inferiority in treating complicated skin and soft tissue infections (cSSTI) compared to vancomycin + aztreonam. A recent pooled analysis of these 3 studies evaluated the impact of age and comorbidities on clinical outcomes.

Source: Anti-Infectives 17. 3. 2023